People assigned to weight-loss surgery were much more likely to experience diabetes remission than people assigned to medical and lifestyle treatment in a long-term study, with remission occurring at some point during follow-up in 58 percent of the surgery group and 3 percent of the comparison group. Participants were followed for a median of 11 years, and some were followed for up to 14 years.
The findings, published in Diabetes Care, show that surgery can have a lasting effect for some people, but diabetes remission was not universal and diabetes sometimes returned. Donald Simonson of Brigham and Women’s Hospital and Harvard Medical School led the analysis. John Kirwan, now at the University of Oklahoma, was the study’s principal investigator.
Researchers analysed data from 262 people with type 2 diabetes who had taken part in randomised trials. Of these, 166 were assigned to metabolic bariatric surgery and 96 to intensive medical and lifestyle management. The researchers defined diabetes remission as an HbA1c below 6.5 percent without medication to lower blood sugar. HbA1c is a blood test that reflects average blood sugar over about three months.
The 58 percent figure describes participants who achieved remission during follow-up. It does not mean that 58 percent stayed in remission without a break for the full 14 years. That distinction matters for patients weighing treatment options, because a return of diabetes after remission is a known outcome and was part of what the study tracked.
Who reached diabetes remission most often
People who had lived with diabetes for fewer years were more likely to achieve diabetes remission. Not using insulin and taking fewer types of blood sugar medicines before treatment were also linked with a greater chance of remission. Greater weight loss during the first year after treatment was another factor linked with remission.
These links describe patterns in the study group. They cannot predict with certainty what will happen to an individual patient, and the researchers were careful to present them as associations rather than guarantees. Age, other health conditions, and the specific operation performed can also shape outcomes, though the published summary focused on duration of diabetes, insulin use, medicine count and early weight loss.
Longer diabetes duration and the use of more types of blood sugar medicines before treatment were linked with a greater likelihood of diabetes returning after an initial remission. That finding fits a wider pattern in diabetes care: the longer blood sugar has been hard to control, the harder it can be to restore control and keep it. It also points to a question the researchers want to answer next, which is who benefits most from each treatment path.
How the diabetes remission study was run
The analysis drew on a group of randomised trials known as ARMMS-T2D. Random assignment helps make treatment groups comparable at the start, since people are placed in a group by chance rather than by choice or by a clinician’s judgement. Later comparisons of patient characteristics and outcomes still rest on associations, and the authors did not claim that every difference between groups was caused by the treatment alone.
Weight-loss surgery is a major intervention, and treatment decisions depend on a person’s health, preferences and medical circumstances. The study compares approaches over a long period, but it does not mean surgery is appropriate or effective for everyone. Medical and lifestyle management remains the right path for many patients, and surgery carries risks and demands follow-up care that must be weighed in each case.
Follow-up over a median of 11 years is unusual in diabetes research, where many trials report results after one or two years. The longer view is what gives this diabetes remission analysis its weight. Short trials can show early blood sugar gains that fade, while a decade of follow-up shows how often gains hold, how often diabetes returns, and which patients keep the benefit.
What diabetes remission means for patients
For a patient, diabetes remission means blood sugar stays below the study threshold without glucose lowering drugs. It does not mean diabetes has been cured in the sense that it can never return, and it does not remove the need for monitoring. Blood sugar, weight, blood pressure and other risk factors still need regular checks, and medicines for other conditions may still be needed.
The results give researchers a clearer view of both the potential for diabetes remission and the possibility of relapse. They also help identify questions for future research on who may benefit most from different treatments, and whether earlier surgery, or surgery combined with newer medicines, changes the long-term picture. The study did not test those combinations, so those questions remain open.